**CLAIMS:**

1. Use of the anti-αv integrin antibody Abituzumab in the manufacture of a medicament for the prophylaxis and/or treatment of fibrosis and/or fibrotic disorders.

2. The use according to claim 1, wherein the organs affected by said fibrosis and/or fibrotic disorders are selected from the group consisting of lung, liver, kidney, cardiovascular system or skin.

3. The use according to claim 1 and/or 2, wherein said fibrotic disorder affects one or more organs selected from the group consisting of lung, liver, kidney, heart and skin.

4. The use according to claim 1, 2 and/or 3, wherein said fibrotic disorder comprises or is systemic sclerosis (SSc).

5. Use of the anti-αv integrin antibody Abituzumab in the manufacture of a medicament for the treatment of systemic sclerosis (SSc).

6. The use according to claim 4 and/or 5, wherein the systemic sclerosis comprises systemic sclerosis of the lung, liver, kidney, cardiovascular system or skin.

7. The use according to of claim 4, 5 and/or 6, wherein the systemic sclerosis affects one or more organs selected from the group consisting of lung, liver, kidney, heart and skin.

8. The use according to claim 4, wherein the systemic sclerosis affects the cardio-vascular system, the blood vessels and/or the blood.

9. The use according to any of the claims 1-8, wherein the fibrotic disorder and/or the systemic sclerosis comprises one or more indications selected from the group consisting of idiophathic pulmonary fibrosis, primary sclerosing cholangitis, non-alcoholic steatohepatitis (NASH), primary focal glomerulosclerosis, primary segmental glomerulosclerosis, diabetic nephropathy, diastolic dysfunction and myelofibrosis.

10. The use according to any of the claims 1-5, wherein said fibrotic disorder and/or systemic sclerosis comprises pulmonary fibrosis and/or alveolitis (interstitial lung disease, ILD).

11. The use according to claim 1, wherein the disease to be treated is systemic sclerosis of the lung and/or skin.

12. The use according to claim 11, wherein the systemic sclerosis of the skin is diffuse cutaneous systemic sclerosis (dcSSc) or limited cutaneous systemic sclerosis (lcSSc).

13. Use of the anti-αv integrin antibody Abituzumab in the manufacture of a medicament for the treatment of pulmonary fibrosis, alveolitis (interstitial lung disease, ILD), and/or sclerodermal interstitial lung disease (SScILD).

14. The use according to any of the claims 1-13, wherein said treatment comprises the administration of a dose, preferably an effective dose, of said antibody, or biologically active variant or modification thereof, in an amount of 500 mg - 3000 mg per month.

15. The use according to any of the claims 1-14, wherein said treatment comprises the administration of a dose, preferably an effective dose, of said antibody, or biologically active variant or modification thereof, in an amount of 1000 mg - 2000 mg per month.

16. The use according to claim 14 and/or 15, wherein the dose, preferably the effective dose, is to be administered in a single dose.

17. The use according to any of the claims 1-15, wherein said treatment comprises the administration of said antibody, or biologically active variant or modification thereof, in an amount of about 500 mg per month, about 1000 mg per month, about 1500 mg per month, about 2000 mg per month or about 2500 mg per month.

18. The use according to claim 17, wherein said amount is to be administered in a single dose.

19. The use according to any of the claims 1-18, wherein said antibody is to be administered as monotherapy.

20. The use according to any of the claims 1-19, wherein the antibody is to be administered in a combination therapy setting in combination with MMF (Mycophenolate).

21. The use according to claim 20, wherein the disorder is Systemic sclerosis (SSc) or Scleroderma-ILD (SSc-ILD).

22. Use of the anti-αv integrin antibody Abituzumab in the manufacture of a medicament for the treatment of fibrosis and/or fibrotic diseases in a subject wherein said subject is characterized by a gene signature, comprising the genes COL15A1 (NM_001855), COL1A1 (NM_000088), COMP (NM_000095), RGS5 (NM_003617), COL10A1 (NM_000493), COL5A 1 (NM_000093), IGFBP2 (NM_000597), NM_005576, MOXD1 (NM_015529), ADRA2A (NM_000681), COL5A2 (NM_000393), MMP10 (NM_002425), TNFRSF21 (NM_014452), ITGA7 (NM_002206), TGF-β3 (NM_003239), MMP11 (NM_005940), SPP1 (NM_000582), CCL2 (NM_002982), and TNC (NM_002160).

23. Use of the anti-αv integrin antibody Abituzumab in the manufacture of a medicament for the treatment of fibrosis and/or fibrotic diseases in a subject wherein said subject is characterized by a gene signature, comprising the genes COL15A1 (NM_001855), COL1A1 (NM_000088), COMP (NM_000095), COL10A1 (NM_000493), COL5A1 (NM_000093), COL5A2 (NM_000393), ITGA7 (NM_002206), MMP11 (NM_005940), and TNC (NM_002160).

24. Use according to claim 22 and/or 23, wherein the fibrosis and/or fibrotic disorders are as defined in on or more of claims 1 to 13.

25. Use of the anti-αv integrin antibody Abituzumab in the manufacture of a medicament for the treatment of fibrosis and/or fibrotic diseases in a subject characterized by a higher-than-threshold score calculated from a multi-gene signature comprising 9 or more genes, or 15 or more genes, selected from the group consisting of the genes COL15A1 (NM~001855), COL1A1 (NM_000088), COMP (NM_000095), RGS5 (NM_003617), COL10A1 (NM_000493), COL5A1 (NM_000093), IGFBP2 (NM_000597), NM_005576, MOXD1 (NM_015529), ADRA2A (NM_000681), COL5A2 (NM_000393), MMP10 (NM_002425),

TNFRSF21 (NM_014452), ITGA7 (NM_002206), TGF-β3 (NM_003239), MMP11 (NM_005940), SPP1 (NM_000582), CCL2 (NM_002982), and TNC (NM_002160).

26. Use of the anti-αv integrin antibody Abituzumab in the manufacture of a medicament for the treatment of fibrosis and/or fibrotic diseases in a subject characterized by a higher-than-threshold score calculated from a 9-gene signature based on the genes COL15A1 (NM_001855), COL1A1 (NM_000088), COMP (NM_000095), COL10A1 (NM_000493), COL5A1 (NM_000093), COL5A2 (NM_000393), ITGA7 (NM_002206), MMP11 (NM_005940), and TNC (NM_002160).

27. The use according to one or more of the preceding claims, wherein the subject will also receive mycophenolate.

28. The use according to one or more of the preceding claims, wherein the disorder is SSc-ILD and/or the subject will also receive mycophenolate.

29. The use according to one or more of the preceding claims wherein the fibrotic disorder and/or the systemic sclerosis comprises one or more indications selected from the group consisting of idiophathic pulmonary fibrosis, primary sclerosing cholangitis, non-alcoholic steatohepatitis (NASH), primary focal glomerulo-sclerosis, primary segmental glomerulosclerosis, diabetic nephropathy, diastolic dysfunction and myelofibrosis.

30. The use according to claim 29, wherein the fibrotic disorder and/or the systemic sclerosis comprises pulmonary fibrosis, alveolitis (interstitial lung disease, ILD), and/or sclerodermal interstitial lung disease (SSc-ILD).

31. The use according to one or more of the preceding claims, wherein the fibrotic disorder and/or the systemic sclerosis comprises focal segmental glomerulosclerosis (FSGS).

32. The use according to one or more of the preceding claims, wherein the treatment when it begins, will additionally comprise the administration of one or more active ingredients, selected from the group consisting of mycophenolic acid, mycophenolate, mycophenolate mofetil, mycophenolate sodium, methotrexate, amethopterin and prednisone.